IDEAYA Biosciences (NASDAQ:IDYA) CEO Yujiro Hata Sells 26,338 Shares of Stock

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) CEO Yujiro Hata sold 26,338 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer directly owned 690,695 shares of the company’s stock, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

IDEAYA Biosciences Trading Down 0.6%

NASDAQ IDYA traded down $0.20 during trading hours on Thursday, hitting $36.06. 548,701 shares of the company’s stock were exchanged, compared to its average volume of 877,582. The firm has a market cap of $3.17 billion, a price-to-earnings ratio of -18.59 and a beta of -0.04. The stock has a 50-day simple moving average of $38.13 and a 200 day simple moving average of $34.29. IDEAYA Biosciences, Inc. has a 1-year low of $26.05 and a 1-year high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The business had revenue of $8.86 million during the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. IDEAYA Biosciences’s quarterly revenue was up 8800.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.88) earnings per share. On average, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Congress Asset Management Co. raised its holdings in IDEAYA Biosciences by 25.5% during the third quarter. Congress Asset Management Co. now owns 147,696 shares of the company’s stock worth $5,674,000 after buying an additional 29,983 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of IDEAYA Biosciences by 21.0% during the second quarter. Tidal Investments LLC now owns 135,847 shares of the company’s stock valued at $5,063,000 after buying an additional 23,538 shares during the last quarter. Nykredit A S bought a new stake in shares of IDEAYA Biosciences during the second quarter worth about $76,000. Allianz Asset Management GmbH bought a new stake in shares of IDEAYA Biosciences during the second quarter worth about $745,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth about $1,452,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Ratings Changes

IDYA has been the topic of several research analyst reports. Citigroup reissued a “market outperform” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Jefferies Financial Group reaffirmed a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Truist Financial cut their price objective on shares of IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Finally, Guggenheim boosted their target price on IDEAYA Biosciences from $54.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and an average price target of $52.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors.

Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma.